Compare Altria Group Inc (MO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs TG Therapeutics Inc — how do they compare? Altria Group Inc trades at $71.68 (market cap $119.25B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Altria Group Inc is far larger — about 14.6× TG Therapeutics Inc's market cap, and Altria Group Inc pays a 6.22% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 154 Days and TG Therapeutics Inc for 16 Days on average.
| MO | TGTX | |
|---|---|---|
Market Cap | $119.25B | $8.16B |
Volume | 11,178,169 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $59.06 |
52-Week Low | $54.72 | $26.94 |
Typical Hold Time | 154 Days | 16 Days |
Enterprise Value | $141.46B | $8.37B |
Dividend Yield | 6.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $71.43, up 2.95% with a bullish technical signal and strong cash flow generation. The stock shows mixed earnings performance with two misses and one beat in recent quarters, while maintaining a 39% net income margin and $9.3B operating cash flow. Recent news highlights the company's 6.6% dividend yield and 60 consecutive annual increases, though some analysts express concerns about negative equity and regulatory challenges.
MO presents a compelling income opportunity with its high dividend yield and consistent payout history, but faces headwinds from declining cigarette volumes and regulatory uncertainty. The stock trades below analyst consensus target of $69.71, offering potential upside if the company successfully navigates its smoke-free transition. Key risks include negative shareholder equity and margin pressure from shifting consumer preferences.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
